This disclosure describes detecting four genetically distinct kinds of inherited myopathy in horses, referred to as Polysaccharide Storage Myopathy type 2 (PSSM2), or in some cases as Myofibrillar Myopathy (MFM).

The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore.

The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.

Compositions and methods for improving plant growth are provided herein. Polynucleotides encoding ferredoxin-thioredoxin reductase proteins, polypeptides encompassing ferredoxin-thioredoxin reductase proteins, and expression constructs for expressing genes of interest whose expression may improve agronomic properties including but not limited to crop yield, biotic and abiotic stress tolerance, and early vigor, plants comprising the polynucleotides, polypeptides, and expression constructs, and methods of producing transgenic plants are also provided.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of proteins and glycoproteins. The methods, systems, components, and compositions may be utilized for incorporating non-standard amino acids (nsAAs) into cell-free synthesized proteins and glycosylating or otherwise modifying the cell-free synthesized proteins in vitro. The nsAAs of the cell-free synthesized protein may be modified via glycosylation or other modification.

The present invention relates to a method of producing a coherent growth substrate product formed of man-made vitreous fibres (MMVF), comprising the steps of (vi) providing MMVF; (vii) providing an uncured binder composition; (viii) providing a superabsorbent polymer; (ix) forming a mixture of the MMVF, the uncured binder composition and the superabsorbent polymer; (x) curing the uncured binder composition in the mixture to form the coherent growth substrate product; wherein the uncured binder composition comprises at least one hydrocolloid.

A mitochondrion-targeting protein nanoparticle, containing related information such as an amino acid sequence thereof, a coding nucleic acid sequence, and a vector and a host expression bacterium for the coding nucleic acid. Under the induction of metal ions, the self-assembled protein nanoparticle mentioned above can be obtained by an Escherichia coli expression system. The protein nanoparticle can be applied in cancer diagnosis and treatment. Compared with existing mitochondrion-targeting small molecules (such as TPP and MPP), the protein nanoparticle can achieve properties of tumor enrichment, mitochondrion targeting, increasing of ROS content in cells, induction of cell apoptosis, inhibiting tumor growth, etc.

Disclosed are compositions and methods for detecting the presence or level of gamma-hydroxybutyric acid (GHB), or for diagnosing GHB toxicity or overdose.

Codon optimized nucleic acid sequences for the long form and short form of RdCVF are provided, as well as recombinant viral vectors, such as AAV, expression cassettes, proviral plasmids or other plasmids containing the codon optimized sequences. Recombinant vectors are provided that express the codon optimized RdCVFL and RdCVF individually, or express two copies of a codon optimized RdCVF or RdCVFL nucleic acid sequence, or both RdCVFL and RdCVF in a single vector or virus. Compositions containing these codon optimized sequences are useful in methods for treating, retarding or halting certain blinding diseases resulting from the absence or inappropriate expression of RdCVF and RdCVFL.

A formaldehyde-free binder composition for mineral fibers which comprises at least one phenol containing compound and at least one protein.